nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ABCG2—Teniposide—lymphatic system cancer	0.178	0.212	CbGbCtD
Vismodegib—ABCG2—Mitoxantrone—lymphatic system cancer	0.124	0.148	CbGbCtD
Vismodegib—ABCG2—Vincristine—lymphatic system cancer	0.0856	0.102	CbGbCtD
Vismodegib—CYP2C19—Teniposide—lymphatic system cancer	0.0795	0.0948	CbGbCtD
Vismodegib—CYP2C9—Teniposide—lymphatic system cancer	0.0661	0.0788	CbGbCtD
Vismodegib—ABCG2—Methotrexate—lymphatic system cancer	0.0518	0.0618	CbGbCtD
Vismodegib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0449	0.0535	CbGbCtD
Vismodegib—CYP3A4—Cytarabine—lymphatic system cancer	0.039	0.0465	CbGbCtD
Vismodegib—CYP3A4—Teniposide—lymphatic system cancer	0.0384	0.0458	CbGbCtD
Vismodegib—ALB—Methotrexate—lymphatic system cancer	0.0357	0.0426	CbGbCtD
Vismodegib—ABCB1—Vincristine—lymphatic system cancer	0.0309	0.0368	CbGbCtD
Vismodegib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0269	0.0321	CbGbCtD
Vismodegib—ABCB1—Methotrexate—lymphatic system cancer	0.0187	0.0223	CbGbCtD
Vismodegib—CYP3A4—Vincristine—lymphatic system cancer	0.0185	0.0221	CbGbCtD
Vismodegib—Azotaemia—Mechlorethamine—lymphatic system cancer	0.00884	0.0547	CcSEcCtD
Vismodegib—Potassium low—Mitoxantrone—lymphatic system cancer	0.00867	0.0537	CcSEcCtD
Vismodegib—Flank pain—Fludarabine—lymphatic system cancer	0.00758	0.0469	CcSEcCtD
Vismodegib—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.00536	0.0332	CcSEcCtD
Vismodegib—Blood potassium decreased—Mitoxantrone—lymphatic system cancer	0.00478	0.0296	CcSEcCtD
Vismodegib—Azotaemia—Carmustine—lymphatic system cancer	0.00367	0.0227	CcSEcCtD
Vismodegib—Azotaemia—Vincristine—lymphatic system cancer	0.0035	0.0217	CcSEcCtD
Vismodegib—Alopecia—Mechlorethamine—lymphatic system cancer	0.00209	0.0129	CcSEcCtD
Vismodegib—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.00207	0.0128	CcSEcCtD
Vismodegib—Dehydration—Fludarabine—lymphatic system cancer	0.00206	0.0128	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00192	0.0119	CcSEcCtD
Vismodegib—Musculoskeletal pain—Vincristine—lymphatic system cancer	0.00189	0.0117	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00174	0.0108	CcSEcCtD
Vismodegib—Blood urea increased—Mitoxantrone—lymphatic system cancer	0.00171	0.0106	CcSEcCtD
Vismodegib—Azotaemia—Methotrexate—lymphatic system cancer	0.0017	0.0105	CcSEcCtD
Vismodegib—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00163	0.0101	CcSEcCtD
Vismodegib—Alopecia—Teniposide—lymphatic system cancer	0.00154	0.00954	CcSEcCtD
Vismodegib—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00146	0.00905	CcSEcCtD
Vismodegib—Hyponatraemia—Carmustine—lymphatic system cancer	0.00142	0.00882	CcSEcCtD
Vismodegib—Hyponatraemia—Vincristine—lymphatic system cancer	0.00136	0.00842	CcSEcCtD
Vismodegib—Alopecia—Fludarabine—lymphatic system cancer	0.00135	0.00839	CcSEcCtD
Vismodegib—Pain in extremity—Vincristine—lymphatic system cancer	0.00135	0.00838	CcSEcCtD
Vismodegib—Malnutrition—Fludarabine—lymphatic system cancer	0.00133	0.00826	CcSEcCtD
Vismodegib—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00132	0.0082	CcSEcCtD
Vismodegib—Hypokalaemia—Carmustine—lymphatic system cancer	0.00129	0.00799	CcSEcCtD
Vismodegib—Weight decreased—Bleomycin—lymphatic system cancer	0.00127	0.00787	CcSEcCtD
Vismodegib—Dehydration—Vincristine—lymphatic system cancer	0.00126	0.00779	CcSEcCtD
Vismodegib—Dehydration—Mitoxantrone—lymphatic system cancer	0.00123	0.00759	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00122	0.00755	CcSEcCtD
Vismodegib—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.0012	0.00746	CcSEcCtD
Vismodegib—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.0012	0.00743	CcSEcCtD
Vismodegib—Pruritus—Mechlorethamine—lymphatic system cancer	0.00119	0.00736	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00119	0.00735	CcSEcCtD
Vismodegib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00115	0.00712	CcSEcCtD
Vismodegib—Arthralgia—Fludarabine—lymphatic system cancer	0.00114	0.00703	CcSEcCtD
Vismodegib—Myalgia—Fludarabine—lymphatic system cancer	0.00114	0.00703	CcSEcCtD
Vismodegib—Decreased appetite—Teniposide—lymphatic system cancer	0.00108	0.00667	CcSEcCtD
Vismodegib—Vomiting—Mechlorethamine—lymphatic system cancer	0.00107	0.00662	CcSEcCtD
Vismodegib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00107	0.00661	CcSEcCtD
Vismodegib—Rash—Mechlorethamine—lymphatic system cancer	0.00106	0.00656	CcSEcCtD
Vismodegib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00106	0.00656	CcSEcCtD
Vismodegib—Weight decreased—Vincristine—lymphatic system cancer	0.00106	0.00655	CcSEcCtD
Vismodegib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00103	0.00638	CcSEcCtD
Vismodegib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00101	0.00627	CcSEcCtD
Vismodegib—Nausea—Mechlorethamine—lymphatic system cancer	0.000999	0.00618	CcSEcCtD
Vismodegib—Alopecia—Bleomycin—lymphatic system cancer	0.000993	0.00615	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000992	0.00614	CcSEcCtD
Vismodegib—Abdominal pain—Teniposide—lymphatic system cancer	0.00098	0.00607	CcSEcCtD
Vismodegib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000964	0.00597	CcSEcCtD
Vismodegib—Dyspepsia—Fludarabine—lymphatic system cancer	0.000959	0.00594	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.000957	0.00592	CcSEcCtD
Vismodegib—Decreased appetite—Fludarabine—lymphatic system cancer	0.000947	0.00586	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00094	0.00582	CcSEcCtD
Vismodegib—Fatigue—Fludarabine—lymphatic system cancer	0.000939	0.00581	CcSEcCtD
Vismodegib—Pain—Fludarabine—lymphatic system cancer	0.000931	0.00577	CcSEcCtD
Vismodegib—Constipation—Fludarabine—lymphatic system cancer	0.000931	0.00577	CcSEcCtD
Vismodegib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00092	0.0057	CcSEcCtD
Vismodegib—Asthenia—Teniposide—lymphatic system cancer	0.000889	0.0055	CcSEcCtD
Vismodegib—Pruritus—Teniposide—lymphatic system cancer	0.000877	0.00543	CcSEcCtD
Vismodegib—Alopecia—Carmustine—lymphatic system cancer	0.000867	0.00537	CcSEcCtD
Vismodegib—Malnutrition—Carmustine—lymphatic system cancer	0.000854	0.00529	CcSEcCtD
Vismodegib—Diarrhoea—Teniposide—lymphatic system cancer	0.000848	0.00525	CcSEcCtD
Vismodegib—Myalgia—Bleomycin—lymphatic system cancer	0.000833	0.00516	CcSEcCtD
Vismodegib—Alopecia—Vincristine—lymphatic system cancer	0.000828	0.00512	CcSEcCtD
Vismodegib—Back pain—Carmustine—lymphatic system cancer	0.000826	0.00511	CcSEcCtD
Vismodegib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000806	0.00499	CcSEcCtD
Vismodegib—Back pain—Vincristine—lymphatic system cancer	0.000789	0.00488	CcSEcCtD
Vismodegib—Vomiting—Teniposide—lymphatic system cancer	0.000788	0.00488	CcSEcCtD
Vismodegib—Asthenia—Fludarabine—lymphatic system cancer	0.000782	0.00484	CcSEcCtD
Vismodegib—Rash—Teniposide—lymphatic system cancer	0.000781	0.00484	CcSEcCtD
Vismodegib—Dermatitis—Teniposide—lymphatic system cancer	0.000781	0.00483	CcSEcCtD
Vismodegib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000778	0.00481	CcSEcCtD
Vismodegib—Pruritus—Fludarabine—lymphatic system cancer	0.000771	0.00477	CcSEcCtD
Vismodegib—Back pain—Mitoxantrone—lymphatic system cancer	0.000768	0.00476	CcSEcCtD
Vismodegib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000745	0.00461	CcSEcCtD
Vismodegib—Nausea—Teniposide—lymphatic system cancer	0.000736	0.00456	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000728	0.0045	CcSEcCtD
Vismodegib—Myalgia—Carmustine—lymphatic system cancer	0.000727	0.0045	CcSEcCtD
Vismodegib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000694	0.0043	CcSEcCtD
Vismodegib—Myalgia—Vincristine—lymphatic system cancer	0.000694	0.0043	CcSEcCtD
Vismodegib—Vomiting—Fludarabine—lymphatic system cancer	0.000693	0.00429	CcSEcCtD
Vismodegib—Rash—Fludarabine—lymphatic system cancer	0.000687	0.00425	CcSEcCtD
Vismodegib—Dermatitis—Fludarabine—lymphatic system cancer	0.000686	0.00425	CcSEcCtD
Vismodegib—Pain—Bleomycin—lymphatic system cancer	0.000683	0.00423	CcSEcCtD
Vismodegib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000676	0.00419	CcSEcCtD
Vismodegib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000676	0.00419	CcSEcCtD
Vismodegib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000653	0.00404	CcSEcCtD
Vismodegib—Nausea—Fludarabine—lymphatic system cancer	0.000647	0.00401	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000635	0.00393	CcSEcCtD
Vismodegib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00063	0.0039	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000606	0.00375	CcSEcCtD
Vismodegib—Decreased appetite—Carmustine—lymphatic system cancer	0.000606	0.00375	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000602	0.00373	CcSEcCtD
Vismodegib—Constipation—Carmustine—lymphatic system cancer	0.000596	0.00369	CcSEcCtD
Vismodegib—Pain—Carmustine—lymphatic system cancer	0.000596	0.00369	CcSEcCtD
Vismodegib—Breast disorder—Methotrexate—lymphatic system cancer	0.000594	0.00368	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00059	0.00366	CcSEcCtD
Vismodegib—Decreased appetite—Vincristine—lymphatic system cancer	0.000578	0.00358	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000575	0.00356	CcSEcCtD
Vismodegib—Fatigue—Vincristine—lymphatic system cancer	0.000574	0.00355	CcSEcCtD
Vismodegib—Asthenia—Bleomycin—lymphatic system cancer	0.000573	0.00355	CcSEcCtD
Vismodegib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00057	0.00353	CcSEcCtD
Vismodegib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00057	0.00353	CcSEcCtD
Vismodegib—Constipation—Vincristine—lymphatic system cancer	0.000569	0.00352	CcSEcCtD
Vismodegib—Pain—Vincristine—lymphatic system cancer	0.000569	0.00352	CcSEcCtD
Vismodegib—Pruritus—Bleomycin—lymphatic system cancer	0.000565	0.0035	CcSEcCtD
Vismodegib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000563	0.00349	CcSEcCtD
Vismodegib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000559	0.00346	CcSEcCtD
Vismodegib—Pain—Mitoxantrone—lymphatic system cancer	0.000554	0.00343	CcSEcCtD
Vismodegib—Constipation—Mitoxantrone—lymphatic system cancer	0.000554	0.00343	CcSEcCtD
Vismodegib—Abdominal pain—Carmustine—lymphatic system cancer	0.000551	0.00341	CcSEcCtD
Vismodegib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000544	0.00337	CcSEcCtD
Vismodegib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00053	0.00328	CcSEcCtD
Vismodegib—Abdominal pain—Vincristine—lymphatic system cancer	0.000526	0.00326	CcSEcCtD
Vismodegib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000512	0.00317	CcSEcCtD
Vismodegib—Vomiting—Bleomycin—lymphatic system cancer	0.000508	0.00314	CcSEcCtD
Vismodegib—Rash—Bleomycin—lymphatic system cancer	0.000504	0.00312	CcSEcCtD
Vismodegib—Dermatitis—Bleomycin—lymphatic system cancer	0.000503	0.00311	CcSEcCtD
Vismodegib—Asthenia—Carmustine—lymphatic system cancer	0.0005	0.0031	CcSEcCtD
Vismodegib—Asthenia—Vincristine—lymphatic system cancer	0.000477	0.00296	CcSEcCtD
Vismodegib—Diarrhoea—Carmustine—lymphatic system cancer	0.000477	0.00295	CcSEcCtD
Vismodegib—Nausea—Bleomycin—lymphatic system cancer	0.000474	0.00294	CcSEcCtD
Vismodegib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000465	0.00288	CcSEcCtD
Vismodegib—Diarrhoea—Vincristine—lymphatic system cancer	0.000455	0.00282	CcSEcCtD
Vismodegib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000443	0.00275	CcSEcCtD
Vismodegib—Vomiting—Carmustine—lymphatic system cancer	0.000443	0.00274	CcSEcCtD
Vismodegib—Rash—Carmustine—lymphatic system cancer	0.00044	0.00272	CcSEcCtD
Vismodegib—Dermatitis—Carmustine—lymphatic system cancer	0.000439	0.00272	CcSEcCtD
Vismodegib—Vomiting—Vincristine—lymphatic system cancer	0.000423	0.00262	CcSEcCtD
Vismodegib—Rash—Vincristine—lymphatic system cancer	0.00042	0.0026	CcSEcCtD
Vismodegib—Dermatitis—Vincristine—lymphatic system cancer	0.000419	0.0026	CcSEcCtD
Vismodegib—Nausea—Carmustine—lymphatic system cancer	0.000414	0.00256	CcSEcCtD
Vismodegib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000412	0.00255	CcSEcCtD
Vismodegib—Rash—Mitoxantrone—lymphatic system cancer	0.000409	0.00253	CcSEcCtD
Vismodegib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000408	0.00253	CcSEcCtD
Vismodegib—Alopecia—Methotrexate—lymphatic system cancer	0.000402	0.00249	CcSEcCtD
Vismodegib—Malnutrition—Methotrexate—lymphatic system cancer	0.000396	0.00245	CcSEcCtD
Vismodegib—Nausea—Vincristine—lymphatic system cancer	0.000395	0.00245	CcSEcCtD
Vismodegib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000387	0.0024	CcSEcCtD
Vismodegib—Nausea—Mitoxantrone—lymphatic system cancer	0.000385	0.00238	CcSEcCtD
Vismodegib—Back pain—Methotrexate—lymphatic system cancer	0.000383	0.00237	CcSEcCtD
Vismodegib—Arthralgia—Methotrexate—lymphatic system cancer	0.000337	0.00209	CcSEcCtD
Vismodegib—Myalgia—Methotrexate—lymphatic system cancer	0.000337	0.00209	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000335	0.00207	CcSEcCtD
Vismodegib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000317	0.00196	CcSEcCtD
Vismodegib—Skin disorder—Methotrexate—lymphatic system cancer	0.000314	0.00194	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000294	0.00182	CcSEcCtD
Vismodegib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000284	0.00176	CcSEcCtD
Vismodegib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000281	0.00174	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000279	0.00173	CcSEcCtD
Vismodegib—Fatigue—Methotrexate—lymphatic system cancer	0.000278	0.00172	CcSEcCtD
Vismodegib—Pain—Methotrexate—lymphatic system cancer	0.000276	0.00171	CcSEcCtD
Vismodegib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000264	0.00163	CcSEcCtD
Vismodegib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000255	0.00158	CcSEcCtD
Vismodegib—Asthenia—Methotrexate—lymphatic system cancer	0.000232	0.00143	CcSEcCtD
Vismodegib—Pruritus—Methotrexate—lymphatic system cancer	0.000228	0.00141	CcSEcCtD
Vismodegib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000221	0.00137	CcSEcCtD
Vismodegib—Vomiting—Methotrexate—lymphatic system cancer	0.000205	0.00127	CcSEcCtD
Vismodegib—Rash—Methotrexate—lymphatic system cancer	0.000204	0.00126	CcSEcCtD
Vismodegib—Dermatitis—Methotrexate—lymphatic system cancer	0.000203	0.00126	CcSEcCtD
Vismodegib—Nausea—Methotrexate—lymphatic system cancer	0.000192	0.00119	CcSEcCtD
